Published in PLoS Med on November 26, 2013
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA (2000) 19.89
A social science perspective on gifts to physicians from industry. JAMA (2003) 7.78
Assessing whether to receive funding support from tobacco, alcohol, gambling and other dangerous consumption industries. Addiction (2007) 5.18
The problem of appraising qualitative research. Qual Saf Health Care (2004) 3.12
The value of pharmaceutical representative visits and medication samples in community-based family practices. J Fam Pract (2000) 2.87
Why corporate power is a public health priority. BMJ (2012) 2.77
Conducting a meta-ethnography of qualitative literature: lessons learnt. BMC Med Res Methodol (2008) 2.28
Why pharmacists belong in the medical home. Health Aff (Millwood) (2010) 2.12
Hip and knee implants: current trends and policy considerations. Health Aff (Millwood) (2008) 1.92
Public health advocacy to change corporate practices: implications for health education practice and research. Health Educ Behav (2005) 1.86
Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch Intern Med (2010) 1.81
Vulnerability of health to market forces. Med Care (2011) 1.65
"Under the radar": nurse practitioner prescribers and pharmaceutical industry promotions. Am J Manag Care (2010) 1.40
Influence of commercial information on prescription quantity in primary care. Eur J Public Health (2002) 1.31
Will the NP workforce grow in the future? New forecasts and implications for healthcare delivery. Med Care (2012) 1.15
Attitudes of academic and clinical researchers toward financial ties in research: a systematic review. Sci Eng Ethics (2005) 1.10
Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med (2009) 1.07
The effect of medication samples on self-reported prescribing practices: a statewide, cross-sectional survey. J Gen Intern Med (2010) 0.93
Pharmacists' perceptions of the pharmaceutical industry. Am J Health Syst Pharm (2005) 0.88
The information sources used by community nurse prescribers. Br J Nurs (2003) 0.87
Soft targets: nurses and the pharmaceutical industry. PLoS Med (2008) 0.85
Distal nursing. Soc Sci Med (2003) 0.83
Empirical uncertainty and moral contest: a qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia. Soc Sci Med (2005) 0.82
Towards understanding the nature of conflict of interest and its application to the discipline of nursing. Nurs Philos (2009) 0.82
Nurses' reported influence on the prescription and use of medication. Int Nurs Rev (2010) 0.81
Distribution of industry-sponsored diaper bags from maternity facilities in Massachusetts. Breastfeed Med (2007) 0.81
Pharmaceutical promotions and conflict of interest in nurse practitioner's decision making: the undiscovered country. J Am Acad Nurse Pract (2005) 0.80
Nurse prescribing: the experiences of psychiatric nurses in the United States. Nurs Stand (2004) 0.80
Nurse prescribers' interactions with and perceptions of pharmaceutical sales representatives. J Clin Nurs (2009) 0.79
The incommensurability of nursing as a practice and the customer service model: an evolutionary threat to the discipline. Nurs Philos (2011) 0.79
Who's keeping the code? Compliance with the international code for the marketing of breast-milk substitutes in Greater Glasgow. Public Health Nutr (2007) 0.78
The effectiveness of pharmaceutical promotion to hospital pharmacists. Am J Hosp Pharm (1966) 0.77
Nurse practitioners' perceptions and participation in pharmaceutical marketing. J Adv Nurs (2009) 0.77
More than a prescriber: gerontological nurse practitioners' perspectives on prescribing and pharmaceutical marketing. Geriatr Nurs (2009) 0.77
'Consumers are patients!' shared decision-making and treatment non-compliance as business opportunity. Transcult Psychiatry (2009) 0.77
"But doctors do it...": nurses' views of gifts and information from the pharmaceutical industry. Ann Pharmacother (2009) 0.76
How do district nurses choose which products to prescribe? Br J Community Nurs (2009) 0.76
Pharmaceutical industry discursives and the marketization of nursing work: a case example. Nurs Philos (2011) 0.76
The tyranny of profit: concentration of wealth, corporate globalization, and the failed US health care system. ANS Adv Nurs Sci (2003) 0.76
Ethics of pharmaceutical company relationships with the nursing profession: no free lunch...and no more pens? Contemp Nurse (2009) 0.76
Industry sponsorship and research outcome. Cochrane Database Syst Rev (2012) 7.44
Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med (2009) 5.15
Journal policy on research funded by the tobacco industry. BMJ (2013) 3.99
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med (2008) 3.57
Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med (2013) 2.49
Financial ties and conflicts of interest between pharmaceutical and tobacco companies. JAMA (2002) 2.43
Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect (2013) 2.21
Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev (2010) 2.11
Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev (2014) 2.10
Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ (2012) 1.58
CONSORT 2010. Lancet (2010) 1.50
Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med (2013) 1.39
Journal policy on research funded by the tobacco industry. Thorax (2013) 1.38
Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. J Clin Epidemiol (2012) 1.28
Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One (2012) 1.19
Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials (2009) 1.19
The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev (2013) 1.12
Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ (2013) 1.07
Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health (2012) 1.05
Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. Public Health Nutr (2009) 0.98
Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med (2009) 0.93
Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev (2013) 0.88
Interventions for tobacco use cessation in people in treatment for or recovery from substance abuse. Cochrane Libr (2012) 0.87
Factors associated with results and conclusions of trials of thiazolidinediones. PLoS One (2009) 0.86
Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. Nicotine Tob Res (2007) 0.83
Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res (2012) 0.81
Review of the quality of pediatric medications in developing countries. J Pharm Sci (2013) 0.81
Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors. Chiropr Osteopat (2010) 0.79
A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev (2014) 0.78
Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev (2015) 0.77
Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder. Psychother Psychosom (2017) 0.76
Instruments for assessing risk of bias and other methodological criteria: Krauth et al. Respond. Environ Health Perspect (2014) 0.75
Systematic reviews: perhaps "the answer to policy makers' prayers"? Environ Health Perspect (2014) 0.75
Clarification of study and citation. Arch Intern Med (2007) 0.75
The Cochrane Library Oversight Committee. Cochrane Database Syst Rev (2011) 0.75
Journal policy on research funded by the tobacco industry. Heart (2013) 0.75
Policies affecting the supply and access of opioid analgesics: a scoping review protocol. JBI Evid Synth (2020) 0.75
Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev (2016) 0.75
Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharm Pract (2010) 0.75
"Muscling in" on state boards of nursing: a report from California. J Emerg Nurs (2005) 0.75